Oncolytic Viral Immunochemotherapy in Patients With Ovarian Cancer
JAMA Oncology Author Interviews
00:00
The Phase Two Trial in Platinum-Resistant Disease
The overall resist response rate in the valuable patients was 54%. 85% of patients had a CA125 response, and the median progress between survival was 11 months. The waterfall plots and the spider plots of response are all rather strikingly positive for phase two trials in platinum-resistant disease.
Play episode from 07:26
Transcript
